Shorting vorasidenib for IDH mutant low-grade glioma

"Shorting vorasidenib for IDH mutant low-grade glioma." Expert Review of Precision Medicine and Drug Development, 9(1), pp. 1–2

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or mending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.